Eva M Gamper1, Francesco Cottone2, Kathrin Sommer2, Richard Norman3, Madeleine King4, Massimo Breccia5, Giovanni Caocci6, Andrea Patriarca7, Giuseppe A Palumbo8, Reinhard Stauder9, Pasquale Niscola10, Uwe Platzbecker11, Jo Caers12, Marco Vignetti2, Fabio Efficace2. 1. Innsbruck Institute of Patient-centered Outcome Research (IIPCOR), Innsbruck, Austria. Electronic address: eva.gamper@iipcor.org. 2. Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center & Health Outcomes Research Unit, Rome, Italy. 3. School of Public Health, Curtin University, Perth, Australia. 4. University of Sydney, School of Psychology, Sydney, NSW, Australia. 5. Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy. 6. Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. 7. Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy. 8. Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", University of Catania, Catania, Italy. 9. Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria. 10. Hematology Unit, Sant'Eugenio Hospital, Rome, Italy. 11. Clinic and Policlinic of Hematology and Cellular Therapy, Hemostaseology, University Hospital Leipzig, Leipzig, Germany. 12. Department of Hematology, CHU de Liège, University of Liege, Liege, Belgium.
Abstract
BACKGROUND: The aim was to investigate the relative validity of the preference-based measure EORTC QLU-C10D in comparison with the EQ-5D-3L in myelodysplastic syndromes (MDS) patients. METHODS: We used data from an international multicentre, observational cohort study of MDS patients. Baseline EORTC QLU-C10D and EQ-5D-3L scores were used and index scores calculated for Italy, Australia, and the UK. Criterion validity was established by Spearman and intraclass correlations (ICC) and Bland-Altman plots. Construct validity was established by the instruments' ability to discriminate known groups, i.e. groups whose health status is expected to differ. RESULTS: We analyzed data from 619 MDS patients (61.1% male; median age 73.8 years). Correlations between theoretically corresponding domains were largely higher than between unrelated domains. ICCs and Bland-Altman plots indicated moderate to good criterion validity. Ceiling effects were lower for the QLU-C10D (4.7%) than for the EQ-5D-3L (22.6%). The EQ-5D-3L failed to discriminate known-groups in two and the QLU-C10D in one of the comparisons; the QLU-C10D's efficiency in doing so was higher in clinical known-groups. Results were comparable between the countries. CONCLUSIONS: The QLU-C10D may be suitable to generate health utilities for economic research in MDS. Responsiveness and minimal important differences need yet to be established.
BACKGROUND: The aim was to investigate the relative validity of the preference-based measure EORTC QLU-C10D in comparison with the EQ-5D-3L in myelodysplastic syndromes (MDS) patients. METHODS: We used data from an international multicentre, observational cohort study of MDSpatients. Baseline EORTC QLU-C10D and EQ-5D-3L scores were used and index scores calculated for Italy, Australia, and the UK. Criterion validity was established by Spearman and intraclass correlations (ICC) and Bland-Altman plots. Construct validity was established by the instruments' ability to discriminate known groups, i.e. groups whose health status is expected to differ. RESULTS: We analyzed data from 619 MDSpatients (61.1% male; median age 73.8 years). Correlations between theoretically corresponding domains were largely higher than between unrelated domains. ICCs and Bland-Altman plots indicated moderate to good criterion validity. Ceiling effects were lower for the QLU-C10D (4.7%) than for the EQ-5D-3L (22.6%). The EQ-5D-3L failed to discriminate known-groups in two and the QLU-C10D in one of the comparisons; the QLU-C10D's efficiency in doing so was higher in clinical known-groups. Results were comparable between the countries. CONCLUSIONS: The QLU-C10D may be suitable to generate health utilities for economic research in MDS. Responsiveness and minimal important differences need yet to be established.
Authors: David Martínez-Cuadrón; Josefina Serrano; José Mariz; Cristina Gil; Mar Tormo; Pilar Martínez-Sánchez; Eduardo Rodríguez-Arbolí; Raimundo García-Boyero; Carlos Rodríguez-Medina; Carmen Martínez-Chamorro; Marta Polo; Juan Bergua; Eliana Aguiar; María L Amigo; Pilar Herrera; Juan M Alonso-Domínguez; Teresa Bernal; Ana Espadana; María J Sayas; Lorenzo Algarra; María B Vidriales; Graça Vasconcelos; Susana Vives; Manuel M Pérez-Encinas; Aurelio López; Víctor Noriega; María García-Fortes; María C Chillón; Juan I Rodríguez-Gutiérrez; María J Calasanz; Jorge Labrador; Juan A López; Blanca Boluda; Rebeca Rodríguez-Veiga; Joaquín Martínez-López; Eva Barragán; Miguel A Sanz; Pau Montesinos Journal: Cancers (Basel) Date: 2022-06-06 Impact factor: 6.575